title: [Tranexamic acid versus aprotinin for the prevention of bleeding during mitral valve surgery ].
abstract: OBJECTIVE
  This retrospective stady has for objective to compare the effect of Tranexamic Acid (TA) to the low dose of aprotinin (AP) in primary mitral valve surgery in terms of blood loss and transfusion requirements.
  
  
  METHODS
  Are included in the study operated patients of a valvulopathy mitral isolated. Two groups of 50 patients are collected. The tranexamic acid group has received 30 mg kg-1 the acid tranexamic and the aprotinin group has received a low regimen as 500,000 UIK of aprotinin. Blood loss by the chest drains are assessed to different times during first 24 hours post cardiopulmonary bypass. In the same way, we have measured the platelet and fibrinogen count. Blood products were administered according to a classic protocol.
  
  
  RESULTS
  The two groups are comparable clinic and echocardiographic parameters what authorizes us an appariement acceptable. Various cardiopulmonary bypass times are almost similar. We noticed a tendency to excessive blood loss processed by low regimen aprotinin and a significant rate difference of platelet and the fibrinogen level. But no complication has been recorded in the two groups.
  
  
  CONCLUSIONS
  This study demonstrates relatively different effect of the two fibrinolytics inhibitors in primary mitral valve surgery. As for the superiority of one of the two produces, it needs a confirmation by a randomised and controlled clinical trial.
authors.affiliation: Service de chirurgie cardiovasculaire, hôpital militaire d'instruction Mohammad V, BP 10100, Hay Riad Rabat, Maroc.
authors.forename: M
authors.initials: M
authors.lastname: Ait Houssa
authors.forename: A
authors.initials: A
authors.lastname: Boulahya
authors.forename: F A
authors.initials: FA
authors.lastname: Wahid
authors.forename: Y
authors.initials: Y
authors.lastname: Elbekkali
authors.forename: B
authors.initials: B
authors.lastname: Amahzoune
authors.forename: C
authors.initials: C
authors.lastname: Selkane
authors.forename: A
authors.initials: A
authors.lastname: Elkirat
authors.forename: K
authors.initials: K
authors.lastname: Jabrani
authors.forename: D
authors.initials: D
authors.lastname: Ibbat
authors.forename: H
authors.initials: H
authors.lastname: Azendour
authors.forename: F
authors.initials: F
authors.lastname: Mamoun
authors.forename: M
authors.initials: M
authors.lastname: Arji
mesh_terms: D000328:Adult; D000933:Antifibrinolytic Agents / Q000008:administration & dosage*; D007611:Aprotinin / Q000008:administration & dosage*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002315:Cardiopulmonary Bypass; D004305:Dose-Response Relationship, Drug; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006349:Heart Valve Diseases / Q000601:surgery; D006490:Hemostatics / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008943:Mitral Valve / Q000601:surgery*; D010976:Platelet Count; D012189:Retrospective Studies; D014148:Tranexamic Acid / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000933:Antifibrinolytic Agents; D006490:Hemostatics; D014148:Tranexamic Acid; D005340:Fibrinogen; D007611:Aprotinin